The head of the Rheumatology Service at Vall d'Hebron University Hospital and of the Rheumatology research group at VHIR is a highly accomplished rheumatologist with a distinguished career in the field.

It is the first international multi-centre clinical trial to analyse the safety and effect of this treatment for an autoimmune disease.

Els estudis avançaran en els camps de les malalties digestives, el VIH, la fatiga crònica, les patologies cardíaques, l’hepatitis, la diabetis i l’oftalmologia.

Lesions present low levels of miR-885-5p, and this increases keratinocyte proliferation, the attraction of inflammatory cells and also the production of inflammatory mediators.

Onze investigadors i investigadores de Vall d’Hebron faran xerrades i tallers amb l’objectiu d’apropar la ciència a tothom.

The research led by Dr. José Alegre has been one of the 21 projects selected in the 19th call for Health Research Grants.

The jury has valued its ability to raise international funds during 2021 and its trajectory as an example of the translation from the clinic to a company.

IMIDomics is a privately held global biotechnology company focused on the discovery and development of novel targets and drugs for the treatment of patients with immune-mediated inflammatory diseases.